Loading…
Live market data via Yahoo Finance · updated 7/12/2026
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform.
The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
CNTA currently trades at $40.02 and has a market capitalization of $6.19B. It is ranked 1222 by market cap. The near-term forecast shows a path of upside, starting with a 2026 average price of $40.02, with a 2026 minimum of $22.02 and a 2026 maximum of $57.04.
Looking further out, the multi-year forecast envisions the average price rising to $101.82 by 2030, $410.40 by 2040, and $830.21 by 2050, with ROI values of 154.4, 925.5, and 1974.5 respectively.
A major floor 39.5% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
Price is pressing into resistance (0.0% away) — a breakout level to watch.
A major ceiling 1.5% above — clearing it would confirm fresh momentum.
Key CNTA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CNTA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $40.50 | Neutral | $40.43 | Buy |
| MA 10 | $40.21 | Buy | $40.27 | Buy |
| MA 20 | $39.99 | Buy | $40.06 | Buy |
| MA 50 | $39.76 | Buy | $38.76 | Buy |
| MA 100 | $34.64 | Buy | $35.58 | Buy |
| MA 200 | $29.63 | Buy | $30.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 78.18 | Sell |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 122.57 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.02 | Buy |
| ROC (12) | 2.04 | Buy |
| Bollinger %B (20,2) | 0.90 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.08 | Buy |
| Awesome (5,34) | 0.63 | Buy |
| Ultimate (7,14,28) | 92.55 | Sell |
| Momentum (10) | 0.78 | Buy |
| Aroon Osc (25) | 60.00 | Buy |
| Hull MA (9) | 40.64 | Sell |
| ADX (14) | 42.00 | Buy |
| ATR (14) | 0.08 | Info |
The 30-day technical picture is bullish. RSI14 is 70, indicating strong momentum, while the 50-day simple moving average is $39.66 and the 200-day simple moving average is $28.96. The stock sits with support at $39.58 and resistance at $40.02. The 30-day range spans from $36.41 up to $43.99, reflecting solid short-term volatility within a tight band.
See what a past investment in CNTAwould be worth at today's price.
$1,000 invested in CNTA on Jun 30, 2025 (≈ 76.103499 CNTA) would be worth
$3,082.19
+$2,082.19 (+208.2%) today · 3.08× · US Dollar
Based on a CNTA entry price of $13.14 vs. today's $40.5.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $40.18 | $1,007.96 | +0.8% |
| 1 month ago | $39.76 | $1,018.61 | +1.9% |
| 3 months ago | $39.72 | $1,019.64 | +2.0% |
| 6 months ago | $25.01 | $1,619.35 | +61.9% |
| 1 year ago | $13.14 | $3,082.19 | +208.2% |
| All time (5.0y) ago | $22.26 | $1,819.41 | +81.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
The multi-year forecast shows a clear bullish trajectory, with the 2030 average price at $101.82 and a ROI of 154.4, the 2040 average price at $410.40 with a ROI of 925.5, and the 2050 average price at $830.21 with a ROI of 1974.5. These projections imply substantial upside into the late 2020s and beyond, particularly into 2040 and 2050. These are estimates, not guarantees, and actual results may vary based on market dynamics and clinical development milestones.
Tap a question to reveal the answer.
Avg $101.82; Min $79.48; Max $138.92; ROI 154.4; Sentiment BULLISH.
Forecasts indicate a bullish path with rising averages through 2030, 2040, and 2050 and increasing ROI (154.4 by 2030, 925.5 by 2040, 1974.5 by 2050), but these are estimates and not guarantees.
2030 max is $138.92, which is below $150.
Avg $410.40; ROI 925.5; Sentiment BULLISH.
2050 max is $1,357.90; Avg $830.21; ROI 1974.5; Sentiment BULLISH.
Centessa Pharmaceuticals plc Community Discussion
0Share your Centessa Pharmaceuticals plc price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.